Abstract
INTRODUCTION: Evidence generation for the health technology assessment (HTA) of a new technology is a long and expensive process with no guarantees that the health technology will be adopted and implemented into a health-care system. This would suggest that there is a greater risk of failure for a company developing a high-cost technology and therefore incentives (such as increasing the funding available for research or additional market exclusivity) may be needed to encourage development of such technologies as has been seen with many high-cost orphan drugs.
AREAS COVERED: This paper discusses some of the key issues relating to the evaluation of high-cost technologies through the use of existing HTA processes and what the challenges will be going forward.
EXPERT OPINION: We propose that while the current HTA process is robust, its evolution into accommodating the incorporation of real-world data and evidence alongside a life-cycle HTA approach should better enable developers to produce the evidence required on effectiveness and cost-effectiveness. This should lead to reduced decision uncertainty for HTA agencies to make adoption decisions in a more timely and efficient manner. Furthermore, budget impact analysis remains important in understanding the actual financial impact on health-care systems and budgets outside of the cost-effectiveness framework used to aid decision-making.
| Original language | English |
|---|---|
| Pages (from-to) | 1177-1183 |
| Number of pages | 7 |
| Journal | Expert Review of Pharmacoeconomics & Outcomes Research |
| Volume | 23 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 28 Sept 2023 |
Bibliographical note
Funding Information:This paper was not funded.
Publisher Copyright:
© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Keywords
- Humans
- Technology, High-Cost
- Uncertainty
- Technology Assessment, Biomedical
- Biomedical Technology
- Orphan Drug Production
- Cost-Benefit Analysis